TCBP's Business Model
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.tcbiopharm.com |
| CEO (Chief Executive Officer) | Bryan Leland Kobel |
| Number of Employees | |
| IPO date | February 11, 2022 |
TCBP Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | GB |
| Address | Maxim 1 |
| City | Motherwell |
| State | None |
| Phone | 44 14 1433 7557 |
| Zip Code | ML1 4WR |
| Other Identifiers | |
| CIK | 0001872812 |
| ISIN | US87807D4007 |
| CUSIP | 87807D103 |
| Open | 1.51 |
| Previous Close | 0.5 |
| Volume | 5.9 Mil. |
| Average Volume | 377.7 Thou. |
| Day’s Range | 0.5 – 1.51 |
| 52 Week Range | 0.08-523.2 |
| MA (50) | 3.18346 |
| MA (200) | 48.27303 |
| Market Cap | 256.5 Thou. |
| Shares Out. | 513 Thou. |
| Earnings Date | Feb 26, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
